Biogen Reports Low Aduhelm Sales Amid Medicare Uncertainty

Biogen reported low sales of Alzheimer’s drug Aduhelm. Although the Centers for Medicare and Medicaid (CMS) are unable to negotiate prices, Biogen is still feeling a major economic impact and the drug’s future is far from certain.

“At first glance, the reported sales for Biogen, Inc./Eisai Co., Ltd.’s newly launched Alzheimer’s treatment Aduhelm (aducanumab) looks like a typo: $300,000 in the third quarter. The criticism concerning Aduhelm’s efficacy, no doubt, has had an impact. But the thinking here is that the explanation for the slow launch is much simpler: CMS.” Read more here.

(Source: Michael McCaughan, Pink Sheet, 10/27/21)